How do you approach a patient with CP-CML who has a history of inadequate response and severe myelotoxicity to multiple TKIs such as imatinib, nilotinib and dasatinib?  

This depends in part, on the status of the disease (transcript levels), the doses of TKIs that have been used, the nadir blood counts, what lineages are involved in myelosuppression, and the comorbidities of the patient. In principle, ponatinib or asciminib could be used. If ponatinib, I would start...